Ashton Thomas Securities’s Genetic Technologies Ltd. GENE Stock Holding History

Ashton Thomas Securities’s Portfolio GENE Stock Details GENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-5	Closed	-$4	–	1245
2024 Q3	$4	Buy	+5	New	+$4	﹤0.01%	1240

Other funds holding GENE

RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return

Ashton Thomas Securities's GENE Position: Q4 2024 in Review

Ashton Thomas Securities sold out of Genetic Technologies Ltd. (GENE) in Q4 2024, closing a stake of 5 shares — an estimated $4 sold.

Ashton Thomas Securities first reported a position in GENE in Q3 2024 and held it in 1 quarter. The position peaked at $4 in Q3 2024. 1 fund tracked by Wall St. Rank holds GENE as of Q4 2024.

Ashton Thomas Securities reported no remaining Genetic Technologies Ltd. position as of Q4 2024 after selling out during the quarter.
Ashton Thomas Securities sold 5 Genetic Technologies Ltd. shares in Q4 2024, an estimated $4.
Ashton Thomas Securities first reported a position in Genetic Technologies Ltd. in Q3 2024 and held it in 1 quarter.
Ashton Thomas Securities's Genetic Technologies Ltd. position peaked at $4 in Q3 2024.
1 fund tracked by Wall St. Rank held Genetic Technologies Ltd. as of Q4 2024.

Based on Ashton Thomas Securities's 13F filing for Q4 2024, filed 11 Feb 2025.